Literature DB >> 8595165

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.

M V Hejmadi1, S R McKeown, O P Friery, I A McIntyre, L H Patterson, D G Hirst.   

Abstract

AQ4N (1,4-bis-([2-(dimethylamino-N- oxide)ethyl]amino)5,8-dihydroxyanthracene-9,10-dione) is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound, AQ4. The alkaline comet assay was used to evaluate DNA damage induced by AQ4N and radiation. Cells prepared from freshly excised T50/80 murine tumours were shown to have the ability to reduce AQ4N to a DNA-damaging agent; this had disappeared within 24 h of excision. When T50/80 tumours implanted in BDF mice were exposed to radiation in vivo a considerable amount of DNA damage was present in tumours excised immediately. Minimal levels of DNA damage were detectable in tumours excised after 2-5 h. AQ4N given 30 min before radiation had no appreciable influence on this effect and AQ4N alone caused only a small amount of damage. When AQ4N and radiation were combined an increasing number of damaged cells were seen in tumours excised 24-96 h after irradiation. This was interpreted as evidence of the continued presence of AQ4, or AQ4-induced damage, which was formed in cells hypoxic at the time of administration of AQ4N. AQ4, a potent topoisomerase II inhibitor, would be capable of damaging cells recruited into the cell cycle following radiation damage to the well-oxygenated cells of the tumour. The kinetics of the expression of the DNA damage is consistent with this hypothesis and shows that AQ4 has persistent activity in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8595165      PMCID: PMC2074454          DOI: 10.1038/bjc.1996.87

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

Review 1.  Molecular assays of radiation-induced DNA damage.

Authors:  S J Whitaker; S N Powell; T J McMillan
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

2.  Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay.

Authors:  P L Olive; J P Banáth; R E Durand
Journal:  Radiat Res       Date:  1990-04       Impact factor: 2.841

Review 3.  The single cell gel electrophoresis assay (comet assay): a European review.

Authors:  V J McKelvey-Martin; M H Green; P Schmezer; B L Pool-Zobel; M P De Méo; A Collins
Journal:  Mutat Res       Date:  1993-07       Impact factor: 2.433

4.  Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone.

Authors:  P Okunieff; M Hoeckel; E P Dunphy; K Schlenger; C Knoop; P Vaupel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-07-15       Impact factor: 7.038

5.  Radiation-induced reoxygenation in the SCCVII murine tumour: evidence for a decrease in oxygen consumption and an increase in tumour perfusion.

Authors:  P L Olive
Journal:  Radiother Oncol       Date:  1994-07       Impact factor: 6.280

6.  Growth fraction measured using the comet assay.

Authors:  P L Olive; J P Banáth
Journal:  Cell Prolif       Date:  1992-09       Impact factor: 6.831

Review 7.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 8.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

9.  AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.

Authors:  S R McKeown; M V Hejmadi; I A McIntyre; J J McAleer; L H Patterson
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

10.  EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.

Authors:  J Collard; A M Matthew; J A Double; M C Bibby
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more
  7 in total

1.  Single-cell gel electrophoresis (SCG)-A review and discussion.

Authors:  Y Lu; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  1997-07       Impact factor: 3.674

2.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

Review 3.  Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.

Authors:  Robert D Bruno; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-05-23       Impact factor: 3.641

4.  The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

Authors:  R Gallagher; C M Hughes; M M Murray; O P Friery; L H Patterson; D G Hirst; S R McKeown
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

5.  Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.

Authors:  L H Patterson; S R McKeown; K Ruparelia; J A Double; M C Bibby; S Cole; I J Stratford
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

Review 6.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

7.  In vitro radiosensitization of breast cancer with hypoxia-activated prodrugs.

Authors:  Radhika Aiyappa-Maudsley; Lina Elsalem; Ali I M Ibrahim; Klaus Pors; Stewart G Martin
Journal:  J Cell Mol Med       Date:  2022-07-16       Impact factor: 5.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.